title: [PI3K-AKT-mTOR pathway and cancer].
abstract: PI3K/AKT/mTOR pathway is an intracellular signalling pathway composed of different kinases. Many protein mutations are described in that pathway, and are responsible of dysregulation of cell growth, proliferation, survival and angiogenesis. Rapamycin is an antibiotic inhibiting mTOR. Different analogs of rapamycin are developed or being developed in antitumoral therapy, in which temsirolimus, everolimus and deforolimus, demonstrated antitumoral activity in renal cancer and mantle cell lymphoma, and many clinical trials are in progress in other tumors. In the future, predictive factors of response need to be identified; patient selection and associations with chemotherapy or with other targeted therapies should be explored.
authors: Hôpital Beaujon, service interhospitalier de cancérologie, 100, boulevard du Général-Leclerc, 92118 Clichy Cedex, France.
authors: Laetitia
authors: L
authors: Coutte
authors: Chantal
authors: C
authors: Dreyer
authors: Marie-Paule
authors: MP
authors: Sablin
authors: Sandrine
authors: S
authors: Faivre
authors: Eric
authors: E
authors: Raymond
mesh_terms: D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D000068338:Everolimus; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000209:etiology; D051058:Oncogene Protein v-akt / Q000037:antagonists & inhibitors* / Q000502:physiology; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology; D020123:Sirolimus / Q000031:analogs & derivatives / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D000068338:Everolimus; D051058:Oncogene Protein v-akt; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; C515074:ridaforolimus; C401859:temsirolimus; C546842:MTOR protein, human